Reimbursement recommendations for new medicines in Canada: current trends in an uncertain era
Nigel S. B. Rawson, PhD | Affiliated scholar/Senior fellow, Canadian Health Policy Institute, Macdonald-Laurier Institute,
Editor
POST CONFERENCE REPORT
The Innovation Legacy: Building a Healthier Future CONFERENCE REPORT Canadian Health Policy Institute (CHPI) and 3Sixty Public
Canada’s medication spending has been relatively low; may need to be reconsidered because of US “most-favored nation” pharma pricing policy
Gerry Jeffcott | 3Sixty Public Affairs | ABSTRACT – Background: Public discourse often frames innovative
Does Canada pay its fair share of the global cost of pharmaceutical innovation?
Brett J Skinner, PhD | CEO, CHPI; Editor, CHPJ | ABSTRACT – The global cost
The Economic Burden of Seasonal Influenza in Quebec: Updated Estimates and Policy Implications
Yanick Labrie, MA | Health Economist, Yanick Labrie Consultant Inc. | ABSTRACT – Seasonal influenza
Bulk purchasing for innovative pharmaceuticals – proceed with caution
Neil Palmer | Independent Consultant | ABSTRACT – The promise of substantial additional cost savings
Net direct expenditure on patented medicines by public drug plans in 10 Canadian provinces in 2023
Brett Skinner, PhD | CEO CHPI, Editor CHPJ | ABSTRACT – Canada’s federal, provincial, and